Intra-Biotech Alliances
This article was originally published in Start Up
Executive Summary
As pharma companies increasingly require their biotech company partners to offer more integrated technology platforms in drug discovery deals, and as more biotech companies take internally developed compounds to later stages of development, the number of intra-biotech company alliances continues to increases Advice of Counsel discusses how these deals differ from traditional alliances between biotech and pharmaceutical companies.
You may also be interested in...
Intra-Biotech Alliances, Part II
What are the critical success factors which cause a joint discovery research partnership between two biotech companies to succeed? Why haven't more of these deals created significant commercial value? Each side needs significant skin in the game. If they don't, and the stakes are low for the partners, the venture remains a low priority and simply doesn't get the proper attention.
Why Clinical Trials Fail Unexpectedly
Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.
Why Investors Adopt Orphans
Venture-backed biotech companies are increasingly seeking to commercialize drugs that qualify for orphan drug protection from the FDA; is this business model a good idea?